NFE2L2 and cancer: The activation of oncogenic proteins (e.g., K−RasG12D, B−RafV619E, and MycERT2) is a hallmark of cancer in which intracellular ROS levels are inhibited by increased NRF2 transcription [70], thereby providing cytoprotection and possibly being associated with a poor response to initial therapy in some patients.